|
1
|
McPherson K, Steel CM and Dixon JM: Breast
cancer-epidemiology, risk factors, and genetics. BMJ. 321:624–628.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Albain KS, Nag SM, CalderilloRuiz G,
Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS,
ReyesVidal JM, Sekhon JS, et al: Gemcitabine plus Paclitaxel versus
Paclitaxel monotherapy in patients with metastatic breast cancer
and prior anthracycline treatment. J Clin Oncol. 26:3950–3957.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Shaughnessy J, Miles D, Vukelja S,
Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY,
Mauriac L, et al: Superior survival with capecitabine plus
docetaxel combination therapy in anthracycline-pretreated patients
with advanced breast cancer: Phase III trial results. J Clin Oncol.
20:2812–2823. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gennari A, Stockler M, Puntoni M, Sormani
M, Nanni O, Amadori D, Wilcken N, D'Amico M, DeCensi A and Bruzzi
P: Duration of chemotherapy for metastatic breast cancer: A
systematic review and meta-analysis of randomized clinical trials.
J Clin Oncol. 29:2144–2149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coates A, Gebski V, Bishop JF, Jeal PN,
Woods RL, Snyder R, Tattersall MH, Byrne M, Harvey V, Gill G, et
al: Improving the quality of life during chemotherapy for advanced
breast cancer. A comparison of intermittent and continuous
treatment strategies. N Engl J Med. 317:1490–1495. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Shaughnessy JA, Kaufmann M, Siedentopf
F, Dalivoust P, Debled M, Robert NJ and Harbeck N: Capecitabine
monotherapy: Review of studies in first-line HER-2-negative
metastatic breast cancer. Oncologist. 17:476–484. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blum JL, Barrios CH, Feldman N, Verma S,
McKenna EF, Lee LF, Scotto N and Gralow J: Pooled analysis of
individual patient data from capecitabine monotherapy clinical
trials in locally advanced or metastatic breast cancer. Breast
Cancer Res Treat. 136:777–788. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rossi D, Alessandroni P, Catalano V,
Giordani P, Fedeli SL, Fedeli A, Baldelli AM, Casadei V, Ceccolini
M and Catalano G: Safety profile and activity of lower capecitabine
dose in patients with metastatic breast cancer. Clin Breast
Cancer7. 857–860. 2007. View Article : Google Scholar
|
|
9
|
Hennessy BT, Gauthier AM, Michaud LB,
Hortobagyi G and Valero V: Lower dose capecitabine has a more
favorable therapeutic index in metastatic breast cancer:
Retrospective analysis of patients treated at M. D. Anderson Cancer
Center and a review of capecitabine toxicity in the literature. Ann
Oncol. 16:1289–1296. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vici P, Giotta F, Di Lauro L, Sergi D,
Vizza E, Mariani L, Latorre A, Pizzuti L, D'Amico C, Giannarelli D,
et al: A multicenter phase II randomized trial of
docetaxel/gemcitabine versus docetaxel/capecitabine as first-line
treatment for advanced breast cancer: A Gruppo Oncologico Italia
Meridionale study. Oncology. 81:230–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soto C, Torrecillas L, Reyes S, Ramirez M,
Perez L, Cervantes G, Gonzalez F, Tellez E, Cortes P and Benitez H:
Capecitabine (X) and taxanes in patients (pts) with
anthracycline-pretreated metastatic breast cancer (MBC): Sequential
vs. combined therapy results from a MOSG randomized phase III
trial. J Clin Oncol (Meeting abstracts). 24:5702006.
|
|
14
|
Park YH, Jung KH, Im SA, Sohn JH, Ro J,
Ahn JH, Kim SB, Nam BH, Oh Y, Han SW, et al: Phase III,
multicenter, randomized trial of maintenance chemotherapy versus
observation in patients with metastatic breast cancer after
achieving disease control with six cycles of gemcitabine plus
paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol.
31:1732–1739. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang H, Jiang Z, Wang T, Zhang S, Bian L,
Cao Y, Wu S and Song S: Single-agent capecitabine maintenance
therapy after response to capecitabine-based combination
chemotherapy in patients with metastatic breast cancer. Anticancer
Drugs. 23:718–723. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bertelli G, Garrone O, Bertolotti L,
Occelli M, Conforti S, Marzano N, Febbraro A, Carlini P, Liossi C,
Del Mastro L, et al: Maintenance hormone therapy with letrozole
after first-line chemotherapy for advanced breast cancer. Oncology.
68:364–370. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gennari A, Amadori D, De Lena M, Nanni O,
Bruzzi P, Lorusso V, Manzione L and Conte PF: Lack of benefit of
maintenance paclitaxel in first-line chemotherapy in metastatic
breast cancer. J Clin Oncol. 24:3912–3918. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alba E, RuizBorrego M, Margelí M,
Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo Jr,
Ramos-Vázquez M, Ribelles N, Calvo E, et al: Maintenance treatment
with pegylated liposomal doxorubicin versus observation following
induction chemotherapy for metastatic breast cancer: GEICAM 2001-01
study. Breast Cancer Res Treat. 122:169–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carrick S, Parker S, Thornton CE, Ghersi
D, Simes J and Wilcken N: Single agent versus combination
chemotherapy for metastatic breast cancer. Cochrane Database Syst
Rev. Apr 15–2009.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
